JUV-161 myopathy program
phase 1drug program · high · Sat Feb 28 2026 00:00:00 GMT+0000 (Coordinated Universal Time)
Develop a tissue-restorative biologic for myotonic dystrophy type 1 and other degenerative myopathies, with clinical testing also assessing effects on muscle disuse atrophy.
Subcutaneous JUV-161 dosing in healthy volunteers, including single- and multiple-ascending-dose safety, tolerability, and pharmacokinetic testing, followed by a randomized placebo-controlled unilateral lower limb immobilization study.
A multicenter New Zealand study of up to 40 healthy volunteers aged 40 to 65 is assessing weekly subcutaneous JUV-161 or placebo over about 6 weeks for muscle disuse atrophy.
Muscle health research collaboration with Lilly
exploratoryresearch program · medium · Wed Jun 11 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Identify muscle-boosting drugs using Juvena's discovery capabilities in collaboration with Eli Lilly.
Research collaboration focused on muscle health; supplied evidence describes a strategic pact with Lilly but does not provide specific targets or assays.
Juvena and Eli Lilly entered a research collaboration valued at up to $650 million in 2025.
Liver disease program
undiscloseddrug program · medium
Develop a biologic medicine for liver disease using Juvena's tissue-restorative secreted-protein platform.
Undisclosed biologic program derived from the AI-enabled secreted protein platform.
Listed as additional work in liver diseases; no specific candidate, trial, or milestone is provided in the supplied material.
Lung disease program
undiscloseddrug program · medium
Develop a biologic medicine for lung disease using Juvena's tissue-restorative secreted-protein platform.
Undisclosed biologic program derived from the AI-enabled secreted protein platform.
Listed as additional work in lung diseases; no specific candidate, trial, or milestone is provided in the supplied material.
Obesity program
undiscloseddrug program · medium
Develop a biologic medicine for obesity using Juvena's tissue-restorative secreted-protein platform.
Undisclosed biologic program derived from the AI-enabled secreted protein platform.
Listed as additional work in obesity; no specific candidate, trial, or milestone is provided in the supplied material.
Sarcopenia program
undiscloseddrug program · medium
Develop a biologic medicine for sarcopenia using Juvena's tissue-restorative secreted-protein platform.
Undisclosed biologic program derived from the AI-enabled secreted protein platform.
Listed as additional work in sarcopenia; no specific candidate, trial, or milestone is provided in the supplied material.
Secreted protein discovery platform
exploratoryplatform · high
Discover and engineer tissue-restorative biologic medicines for myopathies, metabolic diseases, and other age-related chronic conditions.
AI-enabled platform that mines proteins secreted by human stem cells, maps proteins to disease phenotypes, screens their ability to restore tissue homeostasis, and engineers selected proteins into biologics.
Platform is being used to support JUV-161 and additional programs in obesity, sarcopenia, lung, and liver diseases.
